<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33925236</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4688</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22094688</ELocationID><Abstract><AbstractText>Neurodegenerative diseases (NDs) including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salman</LastName><ForeName>Mootaz M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-5683-1706</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3QX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, University of Oxford, South Parks Road, Oxford OX1 3QX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Obaidi</LastName><ForeName>Zaid</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-3488-4572</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf 54001, Iraq.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Karbala 56001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitchen</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1558-4673</Identifier><AffiliationInfo><Affiliation>School of Biosciences, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loreto</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3QX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bill</LastName><ForeName>Roslyn M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-1331-0852</Identifier><AffiliationInfo><Affiliation>School of Biosciences, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade-Martins</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3QX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, University of Oxford, South Parks Road, Oxford OX1 3QX, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/P007058/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K-1003</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1003</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/D012910/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>H-1102</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024962/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>H-1301</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>182</GrantID><Acronym>ALZS_</Acronym><Agency>Alzheimer's Society</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>J-0901</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>210904/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0801</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400144</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N029453/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">CADD</Keyword><Keyword MajorTopicYN="N">CNS disorders</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">brain diseases</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33925236</ArticleId><ArticleId IdType="pmc">PMC8124449</ArticleId><ArticleId IdType="doi">10.3390/ijms22094688</ArticleId><ArticleId IdType="pii">ijms22094688</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maciejczyk M., Zalewska A. Salivary redox biomarkers in selected neurodegenerative diseases. J. Clin. Med. 2020;9:497. doi: 10.3390/jcm9020497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020497</ArticleId><ArticleId IdType="pmc">PMC7074092</ArticleId><ArticleId IdType="pubmed">32059422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabanel J.-M., Perrotte M., Ramassamy C. Nanobiotechnology in Neurodegenerative Diseases. Springer; Berlin/Heidelberg, Germany: 2019. Nanotechnology at the Rescue of Neurodegenerative Diseases: Tools for Early Diagnostic; pp. 19&#x2013;48.</Citation></Reference><Reference><Citation>Sehgal S.A., Hammad M.A., Tahir R.A., Akram H.N., Ahmad F. Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Curr. Neuropharmacol. 2018;16:649&#x2013;663. doi: 10.2174/1570159X16666180315142137.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X16666180315142137</ArticleId><ArticleId IdType="pmc">PMC6080102</ArticleId><ArticleId IdType="pubmed">29542412</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Brayne C., Burns A., Cohen-Mansfield J., Cooper C. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413&#x2013;446. doi: 10.1016/S0140-6736(20)30367-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M., Knapp M., Guerchet M., McCrone P., Prina M., Comas-Herrera A., Wittenberg R., Adelaja B., Hu B., King D. Dementia UK: Update. Alzheimers Society; Belfast, UK: 2014. pp. 1&#x2013;136.</Citation></Reference><Reference><Citation>Prime Minister&#x2019;s Challenge on Dementia.  [(accessed on 14 April 2020)]; Available online:  https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia-2020.</Citation></Reference><Reference><Citation>Shukla R., Singh T.R. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer&#x2019;s disease. J. Biomol. Struct. Dyn. 2020;38:248&#x2013;262. doi: 10.1080/07391102.2019.1571947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2019.1571947</ArticleId><ArticleId IdType="pubmed">30688165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouchlis V.D., Melagraki G., Zacharia L.C., Afantitis A. Computer-Aided Drug Design of &#x3b2;-Secretase, &#x3b3;-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer&#x2019;s Therapeutics. Int. J. Mol. Sci. 2020;21:703. doi: 10.3390/ijms21030703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030703</ArticleId><ArticleId IdType="pmc">PMC7038192</ArticleId><ArticleId IdType="pubmed">31973122</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Ende D.J., Am Ende M.T. Chemical engineering in the pharmaceutical industry: An introduction. Chem. Eng. Pharm. Ind. Drug Prod. Des. Dev. Modeling. 2019:1&#x2013;17. doi: 10.1002/9781119600800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9781119600800</ArticleId></ArticleIdList></Reference><Reference><Citation>Talele T.T., Khedkar S.A., Rigby A.C. Successful applications of computer aided drug discovery: Moving drugs from concept to the clinic. Curr. Top. Med. Chem. 2010;10:127&#x2013;141. doi: 10.2174/156802610790232251.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156802610790232251</ArticleId><ArticleId IdType="pubmed">19929824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik A.C., Kumar A., Bharadwaj S., Chaudhary R., Sahi S. Bioinformatics Techniques for Drug Discovery. Springer; Berlin/Heidelberg, Germany: 2018. Structure-Based Approach for In-silico Drug Designing; pp. 21&#x2013;25.</Citation></Reference><Reference><Citation>Hamad O., Amran S., Sabbah A. Drug Discovery-Yesterday and Tomorrow: The Common Approaches in Drug Design and Cancer. Cell Cell. Life Sci. J. 2018;3:000119.</Citation></Reference><Reference><Citation>Lu W., Zhang R., Jiang H., Zhang H., Luo C. Computer-Aided Drug Design in Epigenetics. Front. Chem. 2018;6 doi: 10.3389/fchem.2018.00057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2018.00057</ArticleId><ArticleId IdType="pmc">PMC5857607</ArticleId><ArticleId IdType="pubmed">29594101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapetanovic I. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chem. Biol. Interact. 2008;171:165&#x2013;176. doi: 10.1016/j.cbi.2006.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2006.12.006</ArticleId><ArticleId IdType="pmc">PMC2253724</ArticleId><ArticleId IdType="pubmed">17229415</ArticleId></ArticleIdList></Reference><Reference><Citation>Macalino S.J.Y., Gosu V., Hong S., Choi S. Role of computer-aided drug design in modern drug discovery. Arch. Pharmacal. Res. 2015;38:1686&#x2013;1701. doi: 10.1007/s12272-015-0640-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-015-0640-5</ArticleId><ArticleId IdType="pubmed">26208641</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M., Cao Y., Fan W., Chen L., Mo Y. Computer-aided drug design: Lead discovery and optimization. Comb. Chem. High Throughput Screen. 2012;15:328&#x2013;337. doi: 10.2174/138620712799361825.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138620712799361825</ArticleId><ArticleId IdType="pubmed">22221065</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A., Blaney J., Blundell T., Clark D., Davis A.M., Ealick S., Kim S.-H., McCammon J.A., Verdonk M., Wijnand M. Computational and Structural Approaches to Drug Discovery: Ligand-Protein Interactions. Royal Society of Chemistry; London, UK: 2007.</Citation></Reference><Reference><Citation>Hauri S., Khakzad H., Happonen L., Teleman J., Malmstr&#xf6;m J., Malmstr&#xf6;m L. Rapid determination of quaternary protein structures in complex biological samples. Nat. Commun. 2019;10:1&#x2013;10. doi: 10.1038/s41467-018-07986-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07986-1</ArticleId><ArticleId IdType="pmc">PMC6331586</ArticleId><ArticleId IdType="pubmed">30643114</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig M.H., Ahmad K., Rabbani G., Danishuddin M., Choi I. Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Curr. Neuropharmacol. 2018;16:740&#x2013;748. doi: 10.2174/1570159X15666171016163510.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666171016163510</ArticleId><ArticleId IdType="pmc">PMC6080097</ArticleId><ArticleId IdType="pubmed">29046156</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhouri F.R., Ghasemi J.B. In Silico studies in drug research against neurodegenerative diseases. Curr. Neuropharmacol. 2018;16:664&#x2013;725. doi: 10.2174/1570159X15666170823095628.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666170823095628</ArticleId><ArticleId IdType="pmc">PMC6080098</ArticleId><ArticleId IdType="pubmed">28831921</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzi M.M., Abdallah H.H., Suroowan S., Jugreet S., Zhang Y., Hu X. In Silico Exploration of Bioactive Phytochemicals Against Neurodegenerative Diseases via Inhibition of Cholinesterases. Curr. Pharm. Des. 2020;26:4151&#x2013;4162. doi: 10.2174/1381612826666200316125517.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826666200316125517</ArticleId><ArticleId IdType="pubmed">32178608</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel J.M., Lehner B. Determining protein structures using deep mutagenesis. Nat. Genet. 2019;51:1177. doi: 10.1038/s41588-019-0431-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0431-x</ArticleId><ArticleId IdType="pmc">PMC7610650</ArticleId><ArticleId IdType="pubmed">31209395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar J., Ranjan T., Kumar R.R., Ansar M., Rajani K., Kumar M., Kumar V., Kumar A. In silico Characterization and Homology Modelling of Potato Leaf Roll Virus (PLRV) Coat Protein. Curr. J. Appl. Sci. Technol. 2019:1&#x2013;8. doi: 10.9734/cjast/2019/v33i230054.</Citation><ArticleIdList><ArticleId IdType="doi">10.9734/cjast/2019/v33i230054</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Navarro S., Prent-Pe&#xf1;aloza L., Rodr&#xed;guez N&#xfa;&#xf1;ez Y.A., S&#xe1;nchez-Aros L., Forero-Doria O., Gonz&#xe1;lez W., Campilllo N.E., Reyes-Parada M., Mart&#xed;nez A., Ram&#xed;rez D. Theoretical and Experimental Approaches AiMed. at Drug Design Targeting Neurodegenerative Diseases. Processes. 2019;7:940. doi: 10.3390/pr7120940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pr7120940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Dai P., Ding D., Del Rosario A., Grant R.A., Pentelute B.L., Laub M.T. Affinity-based capture and identification of protein effectors of the growth regulator ppGpp. Nat. Chem. Biol. 2019;15:141&#x2013;150. doi: 10.1038/s41589-018-0183-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-018-0183-4</ArticleId><ArticleId IdType="pmc">PMC6366861</ArticleId><ArticleId IdType="pubmed">30559427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.S., Li Y., Dahoun T., Vogel H., Yuan S. New binding sites, new opportunities for GPCR drug discovery. Trends Biochem. Sci. 2019;44:312&#x2013;330. doi: 10.1016/j.tibs.2018.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2018.11.011</ArticleId><ArticleId IdType="pubmed">30612897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Qiao S., Ji S., Han N., Liu D., Zhou J. Identification of DNA&#x2013;protein binding sites by bootstrap multiple convolutional neural networks on sequence information. Eng. Appl. Artif. Intell. 2019;79:58&#x2013;66. doi: 10.1016/j.engappai.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.engappai.2019.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W., Wang W., Jiang C., Yu Q., Chen H. Molecular dynamics simulations of amyloid fibrils: An in silico approach. Acta Biochim. Biophys. Sin. 2013;45:503&#x2013;508. doi: 10.1093/abbs/gmt026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmt026</ArticleId><ArticleId IdType="pubmed">23532062</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarasen A., Kuno M., Patnin S., Reukngam N., Khlaychan P., Deeyohe S., Intachote P., Saimanee B., Sengsai S., Boonsri P. Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Drug Res. 2019;69:671&#x2013;682. doi: 10.1055/a-0968-1150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-0968-1150</ArticleId><ArticleId IdType="pubmed">31698495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S., Sobarzo-S&#xe1;nchez E., Uriarte E. In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies. Curr. Med. Chem. 2019;26:1746&#x2013;1760. doi: 10.2174/0929867325666171129121924.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867325666171129121924</ArticleId><ArticleId IdType="pubmed">29189117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes R.R., Fonseca A.L.D., Pinto A.C.D.S., Maia E.H.B., Silva A.M.D., Varotti F.D.P., Taranto A.G. Brazilian malaria molecular targets (BraMMT): Selected receptors for virtual high-throughput screening experiments. Mem&#xf3;rias Do Inst. Oswaldo Cruz. 2019;114:e180465. doi: 10.1590/0074-02760180465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0074-02760180465</ArticleId><ArticleId IdType="pmc">PMC6388387</ArticleId><ArticleId IdType="pubmed">30810604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerroug A., Belaidi S., BenBrahim I., Sinha L., Chtita S. Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs. J. King Saud Univ. Sci. 2019;31:595&#x2013;601. doi: 10.1016/j.jksus.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jksus.2018.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira T., Magalhaes R., Sousa S. Tailoring specialized scoring functions for more efficient virtual screening. Frontiers. 2019;2:1&#x2013;4.</Citation></Reference><Reference><Citation>Ray R. Understanding the Structural Importance of the Non-Binding and Binding Parts of Bedaquiline and Its Analogues with ATP Synthase Subunit C Using Molecular Docking, Molecular Dynamics Simulation and 3D-QSAR Techniques; Proceedings of the International Conference on Drug Discovery (ICDD) 2020; Hyderabad, India. 19 February 2020.</Citation></Reference><Reference><Citation>Kotzabasaki M.I., Sotiropoulos I., Sarimveis H. QSAR modeling of the toxicity classification of superparamagnetic iron oxide nanoparticles (SPIONs) in stem-cell monitoring applications: An integrated study from data curation to model development. RSC Adv. 2020;10:5385&#x2013;5391. doi: 10.1039/C9RA09475J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9RA09475J</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbeddy G., Egodawatta P., Goonetilleke A., Ayoko G., Chen L. Application of quantitative structure-activity relationship (QSAR) model in comprehensive human health risk assessment of PAHs, and alkyl-, nitro-, carbonyl-, and hydroxyl-PAHs laden in urban road dust. J. Hazard. Mater. 2020;383:121154. doi: 10.1016/j.jhazmat.2019.121154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhazmat.2019.121154</ArticleId><ArticleId IdType="pubmed">31525685</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M., Qiu Y., Li Q., Li Y. Efficacy coefficient method assisted quadruple-activities 3D-QSAR pharmacophore model for application in environmentally friendly PAE molecular modification. Environ. Sci. Pollut. Res. Int. 2020;27:24103&#x2013;24114. doi: 10.1007/s11356-020-08725-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-020-08725-0</ArticleId><ArticleId IdType="pubmed">32301091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan F., Warshaviak D.T., Hamadeh H.K., Dunn R.T. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs. PLoS ONE. 2019;14:e0204378. doi: 10.1371/journal.pone.0204378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0204378</ArticleId><ArticleId IdType="pmc">PMC6317804</ArticleId><ArticleId IdType="pubmed">30605479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L., Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019;15:565&#x2013;581. doi: 10.1038/s41582-019-0244-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0244-7</ArticleId><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza-Moraga M., Caballero J., Gaube F., Winckler T., Santos L.S. 1-Benzyl-1,2,3,4-tetrahydro-&#x3b2;-carboline as channel blocker of N-methyl-D-aspartate receptors. Chem. Biol. Drug Des. 2012;79:594&#x2013;599. doi: 10.1111/j.1747-0285.2012.01317.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-0285.2012.01317.x</ArticleId><ArticleId IdType="pubmed">22226015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra C.B., Kumari S., Manral A., Prakash A., Saini V., Lynn A.M., Tiwari M. Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer&#x2019;s disease. Eur. J. Med. Chem. 2017;125:736&#x2013;750. doi: 10.1016/j.ejmech.2016.09.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.09.057</ArticleId><ArticleId IdType="pubmed">27721157</ArticleId></ArticleIdList></Reference><Reference><Citation>Samadi A., de la Fuente Revenga M., P&#xe9;rez C., Iriepa I., Moraleda I., Rodr&#xed;guez-Franco M.I., Marco-Contelles J. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer&#x2019;s disease. Eur. J. Med. Chem. 2013;67:64&#x2013;74. doi: 10.1016/j.ejmech.2013.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2013.06.021</ArticleId><ArticleId IdType="pubmed">23838422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha C.H.H., Fatima A., Gaurav A. In Silico investigation of flavonoids as potential trypanosomal nucleoside hydrolase inhibitors. Adv. Bioinform. 2015;2015:1&#x2013;10. doi: 10.1155/2015/826047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/826047</ArticleId><ArticleId IdType="pmc">PMC4660014</ArticleId><ArticleId IdType="pubmed">26640486</ArticleId></ArticleIdList></Reference><Reference><Citation>De Andrade Teles R.B., Diniz T.C., Costa Pinto T.C., de Oliveira J&#xfa;nior R.G., Gama E Silva M., de Lavor &#xc9;.M., Fernandes A.W.C., de Oliveira A.P., de Almeida Ribeiro F.P.R., da Silva A.A.M., et al. Flavonoids as Therapeutic Agents in Alzheimer&#x2019;s and Parkinson&#x2019;s Diseases: A Systematic Review of Preclinical Evidences. Oxidative Med. Cell. Longev. 2018;2018:1&#x2013;21. doi: 10.1155/2018/7043213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7043213</ArticleId><ArticleId IdType="pmc">PMC5971291</ArticleId><ArticleId IdType="pubmed">29861833</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H., Wu G., Chen J., Zhang X., Xiong C., Lei Y., Chen W., Ruan J. (2S)-5, 2&#x2032;, 5&#x2032;-trihydroxy-7-methoxyflavanone, a natural product from abacopteris penangiana, presents neuroprotective effects in vitro and in vivo. Neurochem. Res. 2013;38:1686&#x2013;1694. doi: 10.1007/s11064-013-1070-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-013-1070-8</ArticleId><ArticleId IdType="pubmed">23670091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelldal M.F., Freyd T., Evenseth L.M., Sylte I., Ring A., Paulsen R.E. Exploring the overlapping binding sites of ifenprodil and EVT -101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling. Pharmacol. Res. Perspect. 2019;7:e00480. doi: 10.1002/prp2.480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.480</ArticleId><ArticleId IdType="pmc">PMC6543015</ArticleId><ArticleId IdType="pubmed">31164987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Chowdhury S., Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer&#x2019;s disease. Bmc Neurosci. 2017;18:76. doi: 10.1186/s12868-017-0394-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0394-8</ArticleId><ArticleId IdType="pmc">PMC5660441</ArticleId><ArticleId IdType="pubmed">29078760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Grossberg G.T. Memantine: A review of studies into its safety and efficacy in treating Alzheimer&#x2019;s disease and other dementias. Clin. Interv. Aging. 2009;4:367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762361</ArticleId><ArticleId IdType="pubmed">19851512</ArticleId></ArticleIdList></Reference><Reference><Citation>Memantine for Treatment of Cognitive Impairment in Patients with Parkinson&#x2019;s Disease and Dementia.  [(accessed on 14 April 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00294554.</Citation></Reference><Reference><Citation>Remya C., Dileep K.V., Tintu I., Variyar E.J., Sadasivan C. Design of potent inhibitors of acetylcholinesterase using morin as the starting compound. Front. Life Sci. 2012;6:107&#x2013;117. doi: 10.1080/21553769.2013.815137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21553769.2013.815137</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y., Qu J., Zhang W., Bai M., Zhou Q., Zhang Z., Li Z., Miao J. Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms. Neuropharmacology. 2016;108:1&#x2013;13. doi: 10.1016/j.neuropharm.2016.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.04.008</ArticleId><ArticleId IdType="pubmed">27067919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadayon M., Garkani-Nejad Z. In silico study combining QSAR, docking and molecular dynamics simulation on 2,4-disubstituted pyridopyrimidine derivatives. J. Recept. Signal Transduct. 2019;39:167&#x2013;174. doi: 10.1080/10799893.2019.1641821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10799893.2019.1641821</ArticleId><ArticleId IdType="pubmed">31354087</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy K.K., Tota S., Tripathi T., Chander S., Nath C., Saxena A.K. Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer&#x2019;s disease. Bioorganic. Med. Chem. 2012;20:6313&#x2013;6320. doi: 10.1016/j.bmc.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2012.09.005</ArticleId><ArticleId IdType="pubmed">23026084</ArticleId></ArticleIdList></Reference><Reference><Citation>Samadi A., Estrada M., P&#xe9;rez C., Rodr&#xed;guez-Franco M.I., Iriepa I., Moraleda I., Chioua M., Marco-Contelles J. Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer&#x2019;s disease: Synthesis, biological assessment, and molecular modeling. Eur. J. Med. Chem. 2012;57:296&#x2013;301. doi: 10.1016/j.ejmech.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2012.09.030</ArticleId><ArticleId IdType="pubmed">23078965</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugaeva E., Chernyuk D., Zhang H., Postnikova T.Y., Pats K., Fedorova E., Poroikov V., Zaitsev A.V., Bezprozvanny I. Derivatives of Piperazines as potential therapeutic agents for Alzheimer&#x2019;s disease. Mol. Pharmacol. 2019;95:337&#x2013;348. doi: 10.1124/mol.118.114348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.118.114348</ArticleId><ArticleId IdType="pmc">PMC6402417</ArticleId><ArticleId IdType="pubmed">30696719</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadaraju K.R., Kumar J.R., Mallesha L., Muruli A., Mohana K.N.S., Mukunda C.K., Sharanaiah U. Virtual Screening and Biological Evaluation of Piperazine Derivatives as Human Acetylcholinesterase Inhibitors. Int. J. Alzheimers Dis. 2013;2013:653962. doi: 10.1155/2013/653962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/653962</ArticleId><ArticleId IdType="pmc">PMC3830860</ArticleId><ArticleId IdType="pubmed">24288651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Lv Y., Jin L., Liang G. Revealing the mechanism of EGCG, Genistein, Rutin, Quercetin, and Silibinin against hIAPP aggregation via computational simulations. Interdiscip. Sci. Comput. Life Sci. 2020;12:59&#x2013;68. doi: 10.1007/s12539-019-00352-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-019-00352-9</ArticleId><ArticleId IdType="pubmed">31894470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingayya G.V., Cheruku S.P., Nayak P.G., Kishore A., Shenoy R., Rao C.M., Krishnadas N. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats. Drug Des. Dev. Ther. 2017;11:1011. doi: 10.2147/DDDT.S103511.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S103511</ArticleId><ArticleId IdType="pmc">PMC5384734</ArticleId><ArticleId IdType="pubmed">28408800</ArticleId></ArticleIdList></Reference><Reference><Citation>Vancraenenbroeck R., De Raeymaecker J., Lobbestael E., Gao F., De Maeyer M., Voet A., Baekelandt V., Taymans J.M. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front. Mol. Neurosci. 2014;7:51. doi: 10.3389/fnmol.2014.00051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00051</ArticleId><ArticleId IdType="pmc">PMC4042160</ArticleId><ArticleId IdType="pubmed">24917786</ArticleId></ArticleIdList></Reference><Reference><Citation>West A.B. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp. Neurol. 2017;298:236&#x2013;245. doi: 10.1016/j.expneurol.2017.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.07.019</ArticleId><ArticleId IdType="pmc">PMC5693612</ArticleId><ArticleId IdType="pubmed">28764903</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi A.K., Banerjee K., Gomes J., Banerjee M. Computational and Functional Characterization of Angiogenin Mutations, and Correlation with Amyotrophic Lateral Sclerosis. PLoS ONE. 2014;9:e111963. doi: 10.1371/journal.pone.0111963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111963</ArticleId><ArticleId IdType="pmc">PMC4221194</ArticleId><ArticleId IdType="pubmed">25372031</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H.-J., Chang T.-T., Chen H.-Y., Chen C.Y.-C. Finding inhibitors of mutant superoxide dismutase-1 for amyotrophic lateral sclerosis therapy from traditional chinese medicine. Evid. Based Complement. Altern. Med. 2014;2014:156276. doi: 10.1155/2014/156276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/156276</ArticleId><ArticleId IdType="pmc">PMC4052194</ArticleId><ArticleId IdType="pubmed">24963318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello O.S., Gonzalez J., Capani F., Barreto G.E. In silico docking reveals possible Riluzole binding sites on Nav1. 6 sodium channel: Implications for amyotrophic lateral sclerosis therapy. J. Theor. Biol. 2012;315:53&#x2013;63. doi: 10.1016/j.jtbi.2012.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2012.09.004</ArticleId><ArticleId IdType="pubmed">22995823</ArticleId></ArticleIdList></Reference><Reference><Citation>Benavides-Serrato A., Saunders J.T., Holmes B., Nishimura R.N., Lichtenstein A., Gera J. Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma. Int. J. Mol. Sci. 2020;21:344. doi: 10.3390/ijms21010344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21010344</ArticleId><ArticleId IdType="pmc">PMC6981868</ArticleId><ArticleId IdType="pubmed">31948038</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N.K., Lin J.H., Lin J.T., Lin C.I., Liu E.M., Lin C.J., Chen W.P., Shen Y.C., Chen H.M., Chen J.B., et al. A new drug design targeting the adenosinergic system for Huntington&#x2019;s disease. PLoS ONE. 2011;6:e20934. doi: 10.1371/journal.pone.0020934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020934</ArticleId><ArticleId IdType="pmc">PMC3119665</ArticleId><ArticleId IdType="pubmed">21713039</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydryskova K., Masek T., Pospisek M. Changing faces of stress: Impact of heat and arsenite treatment on the composition of stress granules. Wiley Interdiscip. Rev. RNA. 2020:e1596. doi: 10.1002/wrna.1596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1596</ArticleId><ArticleId IdType="pubmed">32362075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010&#x2013;2050) estimated using the 2010 census. Neurology. 2013;80:1778&#x2013;1783. doi: 10.1212/WNL.0b013e31828726f5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828726f5</ArticleId><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M., Knapp M., Guerchet M., McCrone P., Prina M., Comas-Herrera A., Wittenberg R., Adelaja B., Hu B., King D. Dementia UK: Overview. Alzheimers Society; Belfast, UK: 2014.</Citation></Reference><Reference><Citation>Mayrhofer A., Shora S. Psychosocial Interventions for Younger People Diagnosed with Dementia: A Focus on Communities; Proceedings of the Young Dementia Annual Conference 2019; London, UK. 20 November 2019;  [(accessed on 28 April 2021)].  Available online:  https://careinfo.org/event/young-dementia-2019/</Citation></Reference><Reference><Citation>Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Tredici K.D. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 2012;71:362&#x2013;381. doi: 10.1097/NEN.0b013e31825018f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., Grenier-Boley B., Lambert J.-C. Genetics of Alzheimer&#x2019;s disease: Where we are, and where we are going. Curr. Opin. Neurobiol. 2020;61:40&#x2013;48. doi: 10.1016/j.conb.2019.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.024</ArticleId><ArticleId IdType="pubmed">31863938</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordone M.P., Salman M.M., Titus H.E., Amini E., Andersen J.V., Chakraborti B., Diuba A.V., Dubouskaya T.G., Ehrke E., Espindola de Freitas A. The energetic brain&#x2013;A review from students to students. J. Neurochem. 2019;151:139&#x2013;165. doi: 10.1111/jnc.14829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14829</ArticleId><ArticleId IdType="pubmed">31318452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedergaard M., Goldman S.A. Glymphatic failure as a final common pathway to dementia. Science. 2020;370:50&#x2013;56. doi: 10.1126/science.abb8739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8739</ArticleId><ArticleId IdType="pubmed">33004510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchen P., Salman M.M., Halsey A.M., Clarke-Bland C., MacDonald J.A., Ishida H., Vogel H.J., Almutiri S., Logan A., Kreida S. Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema. Cell. 2020;181:784&#x2013;799.e719. doi: 10.1016/j.cell.2020.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7242911</ArticleId><ArticleId IdType="pubmed">32413299</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman M.M., Sheilabi M.A., Bhattacharyya D., Kitchen P., Conner A.C., Bill R.M., Woodroofe M.N., Conner M.T., Princivalle A.P. Transcriptome analysis suggests a role for the differential expression of cerebral aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy. Eur. J. Neurosci. 2017;46:2121&#x2013;2132. doi: 10.1111/ejn.13652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13652</ArticleId><ArticleId IdType="pubmed">28715131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvain N.J., Salman M.M., Pushie M.J., Hou H., Meher V., Herlo R., Peeling L., Kelly M.E. The effects of trifluoperazine on brain edema, aquaporin-4 expression, and metabolic markers during the acute phase of stroke using photothrombotic mouse model. Biochim. Et Biophys. Acta (BBA) Biomembr. 2021;1863:183573. doi: 10.1016/j.bbamem.2021.183573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2021.183573</ArticleId><ArticleId IdType="pubmed">33561476</ArticleId></ArticleIdList></Reference><Reference><Citation>Abir-Awan M., Kitchen P., Salman M.M., Conner M.T., Conner A.C., Bill R.M. Inhibitors of mammalian aquaporin water channels. Int. J. Mol. Sci. 2019;20:1589. doi: 10.3390/ijms20071589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20071589</ArticleId><ArticleId IdType="pmc">PMC6480248</ArticleId><ArticleId IdType="pubmed">30934923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchen P., Day R.E., Taylor L.H., Salman M.M., Bill R.M., Conner M.T., Conner A.C. Identification and molecular mechanisms of the rapid tonicity-induced relocalization of the aquaporin 4 channel. J. Biol. Chem. 2015;290:16873&#x2013;16881. doi: 10.1074/jbc.M115.646034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.646034</ArticleId><ArticleId IdType="pmc">PMC4505433</ArticleId><ArticleId IdType="pubmed">26013827</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman M.M., Kitchen P., Woodroofe M.N., Brown J.E., Bill R.M., Conner A.C., Conner M.T. Hypothermia increases aquaporin 4 (AQP4) plasma membrane abundance in human primary cortical astrocytes via a calcium/transient receptor potential vanilloid 4 (TRPV4)- and calmodulin-mediated mechanism. Eur. J. Neurosci. 2017;46:2542&#x2013;2547. doi: 10.1111/ejn.13723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13723</ArticleId><ArticleId IdType="pmc">PMC5765450</ArticleId><ArticleId IdType="pubmed">28925524</ArticleId></ArticleIdList></Reference><Reference><Citation>Akincioglu H., Gulcin I. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer&#x2019;s Disease. Mini Rev. Med. Chem. 2020 doi: 10.2174/1389557520666200103100521.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557520666200103100521</ArticleId><ArticleId IdType="pubmed">31902355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H., Song P., Li J., Zhao D. Effect of Salvia miltiorrhiza on acetylcholinesterase: Enzyme kinetics and interaction mechanism merging with molecular docking analysis. Int. J. Biol. Macromol. 2019;135:303&#x2013;313. doi: 10.1016/j.ijbiomac.2019.05.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2019.05.132</ArticleId><ArticleId IdType="pubmed">31128195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram H., Jaipal N., Kumar P., Deka P., Kumar S., Kashyap P., Kumar S., Singh B.P., Alqarawi A.A., Hashem A., et al. Dual Inhibition of DPP-4 and Cholinesterase Enzymes by the Phytoconstituents of the Ethanolic Extract of Prosopis cineraria Pods: Therapeutic Implications for the Treatment of Diabetes-associated Neurological Impairments. Curr. Alzheimer Res. 2019;16:1230&#x2013;1244. doi: 10.2174/1567205016666191203161509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205016666191203161509</ArticleId><ArticleId IdType="pubmed">31797759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder M.K., Choudhury S. Tea polyphenols as multi-target therapeutics for Alzheimer&#x2019;s disease: An in silico study. Med. Hypotheses. 2019;125:94&#x2013;99. doi: 10.1016/j.mehy.2019.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2019.02.035</ArticleId><ArticleId IdType="pubmed">30902161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M.A., Vuree S., Goud H., Hussain T., Nayarisseri A., Singh S.K. Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer&#x2019;s Disease. Curr. Top. Med. Chem. 2019;19:1173&#x2013;1187. doi: 10.2174/1568026619666190617155326.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026619666190617155326</ArticleId><ArticleId IdType="pubmed">31244427</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amelio M., Sheng M., Cecconi F. Caspase-3 in the central nervous system: Beyond apoptosis. Trends Neurosci. 2012;35:700&#x2013;709. doi: 10.1016/j.tins.2012.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2012.06.004</ArticleId><ArticleId IdType="pubmed">22796265</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbriani P., Tassone A., Meringolo M., Ponterio G., Madeo G., Pisani A., Bonsi P., Martella G. Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson&#x2019;s Disease. Int. J. Mol. Sci. 2019;20:3407. doi: 10.3390/ijms20143407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20143407</ArticleId><ArticleId IdType="pmc">PMC6678522</ArticleId><ArticleId IdType="pubmed">31336695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavanagh E., Rodhe J., Burguillos M.A., Venero J.L., Joseph B. Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia. Cell Death Dis. 2014;5:e1565. doi: 10.1038/cddis.2014.514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.514</ArticleId><ArticleId IdType="pmc">PMC4454160</ArticleId><ArticleId IdType="pubmed">25501826</ArticleId></ArticleIdList></Reference><Reference><Citation>Snigdha S., Smith E.D., Prieto G.A., Cotman C.W. Caspase-3 activation as a bifurcation poInt. between plasticity and cell death. Neurosci. Bull. 2012;28:14&#x2013;24. doi: 10.1007/s12264-012-1057-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-012-1057-5</ArticleId><ArticleId IdType="pmc">PMC3838299</ArticleId><ArticleId IdType="pubmed">22233886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancela S., Canclini L., Mourglia-Ettlin G., Hern&#xe1;ndez P., Merlino A. Neuroprotective effects of novel nitrones: In vitro and in silico studies. Eur. J. Pharmacol. 2020;871:172926. doi: 10.1016/j.ejphar.2020.172926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.172926</ArticleId><ArticleId IdType="pubmed">31958456</ArticleId></ArticleIdList></Reference><Reference><Citation>Goubau C., Jaeken J., Levtchenko E.N., Thys C., Di Michele M., Martens G.A., Gerlo E., De Vos R., Buyse G.M., Goemans N., et al. Homozygosity for aquaporin 7 G264V in three unrelated children with hyperglyceroluria and a mild platelet secretion defect. Genet Med. 2013;15:55&#x2013;63. doi: 10.1038/gim.2012.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2012.90</ArticleId><ArticleId IdType="pubmed">22899094</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig N.H., Reale M., Tata A.M. New pharmacological approaches to the cholinergic system: An overview on muscarinic receptor ligands and cholinesterase inhibitors. Recent Pat. CNS Drug Discov. 2013;8:123&#x2013;141. doi: 10.2174/1574889811308020003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574889811308020003</ArticleId><ArticleId IdType="pmc">PMC5831731</ArticleId><ArticleId IdType="pubmed">23597304</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpato D., Holzgrabe U. Designing hybrids targeting the cholinergic system by modulating the muscarinic and nicotinic receptors: A concept to treat Alzheimer&#x2019;s disease. Molecules. 2018;23:3230. doi: 10.3390/molecules23123230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23123230</ArticleId><ArticleId IdType="pmc">PMC6320942</ArticleId><ArticleId IdType="pubmed">30544533</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch A., Bonus M., Gohlke H., Kl&#xf6;cker N. Isoform-specific Inhibition of N-methyl-D-aspartate Receptors by Bile Salts. Sci. Rep. 2019;9:1&#x2013;17. doi: 10.1038/s41598-019-46496-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-46496-y</ArticleId><ArticleId IdType="pmc">PMC6624251</ArticleId><ArticleId IdType="pubmed">31296930</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X., Jensen M.O., Jogini V., Stein R.A., Lee C.H., McHaourab H.S., Shaw D.E., Gouaux E. Mechanism of NMDA receptor channel block by MK-801 and memantine. Nature. 2018;556:515&#x2013;519. doi: 10.1038/s41586-018-0039-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0039-9</ArticleId><ArticleId IdType="pmc">PMC5962351</ArticleId><ArticleId IdType="pubmed">29670280</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts H., Grossberg G.T. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer&#x2019;s disease. J. Clin. Pharmacol. 2006;46:8s&#x2013;16s. doi: 10.1177/0091270006288734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270006288734</ArticleId><ArticleId IdType="pubmed">16809810</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Ganeshpurkar A., Kumar D., Kumar D., Kumar A., Singh S.K. Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: An integrative in silico and molecular modeling approach. J. Biomol. Struct. Dyn. 2019:1&#x2013;13. doi: 10.1080/07391102.2019.1635530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2019.1635530</ArticleId><ArticleId IdType="pubmed">31232189</ArticleId></ArticleIdList></Reference><Reference><Citation>Waqar M., Batool S. In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer&#x2019;s disease. J. Venom. Anim. Toxins Incl. Trop. Dis. 2017;23:42. doi: 10.1186/s40409-017-0132-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40409-017-0132-9</ArticleId><ArticleId IdType="pmc">PMC5607497</ArticleId><ArticleId IdType="pubmed">28943883</ArticleId></ArticleIdList></Reference><Reference><Citation>Alokam R., Singhal S., Srivathsav G.S., Garigipati S., Puppala S., Sriram D., Perumal Y. Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder. Mol. Biosyst. 2015;11:607&#x2013;617. doi: 10.1039/C4MB00570H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4MB00570H</ArticleId><ArticleId IdType="pubmed">25465055</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson D.S., Oliver P.L. ROS generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants. 2020;9:743. doi: 10.3390/antiox9080743.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9080743</ArticleId><ArticleId IdType="pmc">PMC7463655</ArticleId><ArticleId IdType="pubmed">32823544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchio A., Marsili L., Mahajan A., Grimberg B., Kauffman M.A., Espay A.J. How Have Advances in Genetic Technology Modified Movement Disorders Nosology? Eur. J. Neurol. 2020 doi: 10.1111/ene.14294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14294</ArticleId><ArticleId IdType="pubmed">32356310</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul D.A., Qureshi A.R.M., Rana A.Q. Peripheral neuropathy in Parkinson&#x2019;s disease. Neurol. Sci. 2020 doi: 10.1007/s10072-020-04407-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04407-4</ArticleId><ArticleId IdType="pubmed">32358706</ArticleId></ArticleIdList></Reference><Reference><Citation>Coundouris S.P., Terrett G., Laakso L., Schweitzer D., Kneebone A., Rendell P.G., Henry J.D. A meta-analytic review of prospection deficits in Parkinson&#x2019;s disease. Neurosci. Biobehav. Rev. 2020;108:34&#x2013;47. doi: 10.1016/j.neubiorev.2019.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.10.016</ArticleId><ArticleId IdType="pubmed">31682884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J., Moyeed R., Carroll C., Albani D., Li X. Gene expression meta-analysis of Parkinson&#x2019;s disease and its relationship with Alzheimer&#x2019;s disease. Mol. Brain. 2019;12:16. doi: 10.1186/s13041-019-0436-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0436-5</ArticleId><ArticleId IdType="pmc">PMC6396547</ArticleId><ArticleId IdType="pubmed">30819229</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson E.J., Lyell V., Bhimjiyani A., Amin J., Kobylecki C., Gregson C.L. Management of fracture risk in Parkinson&#x2019;s: A revised algorithm and focused review of treatments. Parkinsonism Relat. Disord. 2019;64:181&#x2013;187. doi: 10.1016/j.parkreldis.2019.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2019.03.021</ArticleId><ArticleId IdType="pubmed">30992234</ArticleId></ArticleIdList></Reference><Reference><Citation>Haunton V.J. Movement disorders: A themed collection. Age Ageing. 2020;49:12&#x2013;15. doi: 10.1093/ageing/afz147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afz147</ArticleId><ArticleId IdType="pubmed">31830237</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe9;lix J.P., Vieira F.H.T., Cardoso &#xc1;.A., Ferreira M.V.G., Franco R.A.P., Ribeiro M.A., Ara&#xfa;jo S.G., Corr&#xea;a H.P., Carneiro M.L. A Parkinson&#x2019;s Disease Classification Method: An Approach Using Gait Dynamics and Detrended Fluctuation Analysis; Proceedings of the 2019 IEEE Canadian Conference of Electrical and Computer Engineering (CCECE); Edmonton, AB, Canada. 5&#x2013;8 May 2019; pp. 1&#x2013;4.</Citation></Reference><Reference><Citation>Chakraborty A., Brauer S., Diwan A. A review of possible therapies for Parkinson&#x2019;s disease. J. Clin. Neurosci. 2020 doi: 10.1016/j.jocn.2020.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2020.03.047</ArticleId><ArticleId IdType="pubmed">32278516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z., Liu H., Wu B. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders. Br. J. Clin. Pharmacol. 2014;77:410&#x2013;420. doi: 10.1111/bcp.12169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12169</ArticleId><ArticleId IdType="pmc">PMC3952716</ArticleId><ArticleId IdType="pubmed">23713800</ArticleId></ArticleIdList></Reference><Reference><Citation>Borovac J.A. Focus: The Aging Brain: Side effects of a dopamine agonist therapy for Parkinson&#x2019;s disease: A mini-review of clinical pharmacology. Yale J. Biol. Med. 2016;89:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797835</ArticleId><ArticleId IdType="pubmed">27505015</ArticleId></ArticleIdList></Reference><Reference><Citation>Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson&#x2019;s disease: A review of the literature. Clin. Ther. 2006;28:1&#x2013;12. doi: 10.1016/j.clinthera.2005.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2005.12.003</ArticleId><ArticleId IdType="pubmed">16490575</ArticleId></ArticleIdList></Reference><Reference><Citation>Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: From structure to function. Physiol. Rev. 1998;78:189&#x2013;225. doi: 10.1152/physrev.1998.78.1.189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.1998.78.1.189</ArticleId><ArticleId IdType="pubmed">9457173</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Foll B., Collo G., Rabiner E.A., Boileau I., Pich E.M., Sokoloff P. Progress in Brain Research. Volume 211. Elsevier; Amsterdam, The Netherlands: 2014. Dopamine D3 receptor ligands for drug addiction treatment: Update on recent findings; pp. 255&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">24968784</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio R., Aloisi G., Silvano E., Rossi M., Millan M.J. Heterodimerization of dopamine receptors: New insights into functional and therapeutic significance. Parkinsonism Relat. Disord. 2009;15:S2&#x2013;S7. doi: 10.1016/S1353-8020(09)70826-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(09)70826-0</ArticleId><ArticleId IdType="pubmed">20123551</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor-Robson N., Booth H., Martin J.G., Gao B., Li K., Doig N., Vowles J., Browne C., Klinger L., Juhasz P. An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. Neurobiol. Dis. 2019;127:512&#x2013;526. doi: 10.1016/j.nbd.2019.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.04.005</ArticleId><ArticleId IdType="pmc">PMC6597903</ArticleId><ArticleId IdType="pubmed">30954703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin W. Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression. J. Clin. Med. 2020;9:1256. doi: 10.3390/jcm9051256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9051256</ArticleId><ArticleId IdType="pmc">PMC7288009</ArticleId><ArticleId IdType="pubmed">32357493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartonikova T., Mensikova K., Kolarikova K., Vodicka R., Vrtel R., Otruba P., Kaiserova M., Vastik M., Mikulicova L., Ovecka J., et al. New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background. Medicine. 2018;97:e12313. doi: 10.1097/MD.0000000000012313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000012313</ArticleId><ArticleId IdType="pmc">PMC6160209</ArticleId><ArticleId IdType="pubmed">30235682</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S.H., Knape M.J., Boassa D., Mumdey N., Kornev A.P., Ellisman M.H., Taylor S.S., Herberg F.W. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGpsi motif in the kinase domain. Proc. Natl. Acad. Sci. USA. 2019;116:14979&#x2013;14988. doi: 10.1073/pnas.1900289116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1900289116</ArticleId><ArticleId IdType="pmc">PMC6660771</ArticleId><ArticleId IdType="pubmed">31292254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N., Chellam J., Kannan R.R. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease. J. Cell. Biochem. 2018;119:4878&#x2013;4889. doi: 10.1002/jcb.26703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26703</ArticleId><ArticleId IdType="pubmed">29369408</ArticleId></ArticleIdList></Reference><Reference><Citation>Flor P.J., Battaglia G., Nicoletti F., Gasparini F., Bruno V. Molecular and Cellular Biology of Neuroprotection in the CNS. Springer; Berlin/Heidelberg, Germany: 2003. Neuroprotective activity of metabotropic glutamate receptor ligands; pp. 197&#x2013;223.</Citation></Reference><Reference><Citation>Montastruc J., Rascol O., Senard J. Glutamate antagonists and Parkinson&#x2019;s disease: A review of clinical data. Neurosci. Biobehav. Rev. 1997;21:477&#x2013;480. doi: 10.1016/S0149-7634(96)00035-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-7634(96)00035-8</ArticleId><ArticleId IdType="pubmed">9195605</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzo A., Dal Bo L., Monti N.C., Crivelli F., Ismaili S., Caccia C., Cattaneo C., Fariello R.G. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 2004;50:77&#x2013;85. doi: 10.1016/j.phrs.2003.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2003.12.004</ArticleId><ArticleId IdType="pubmed">15082032</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocchi F., Arnold G., Onofrj M., Kwiecinski H., Szczudlik A., Thomas A., Bonuccelli U., Van Dijk A., Cattaneo C., Sala P. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746&#x2013;748. doi: 10.1212/01.WNL.0000134672.44217.F7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000134672.44217.F7</ArticleId><ArticleId IdType="pubmed">15326260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee A., Palovcak M. The role of augmentative communication devices in the medical management of ALS. NeuroRehabilitation. 2007;22:445&#x2013;450. doi: 10.3233/NRE-2007-22607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NRE-2007-22607</ArticleId><ArticleId IdType="pubmed">18198430</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Liu Z. Opportunities for neuroprotection in ALS using cell death mechanism rationales. Drug Discov. Today Dis. Models. 2004;1:135&#x2013;143. doi: 10.1016/j.ddmod.2004.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddmod.2004.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer P., Kato A.C. Playing defense against Lou Gehrig&#x2019;s disease. Sci. Am. 2007;297:86&#x2013;93. doi: 10.1038/scientificamerican1107-86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/scientificamerican1107-86</ArticleId><ArticleId IdType="pubmed">17990828</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Torres A.S., O&#x2019;Halloran T.V. Oxygen-induced maturation of SOD1: A key role for disulfide formation by the copper chaperone CCS. EMBO J. 2004;23:2872&#x2013;2881. doi: 10.1038/sj.emboj.7600276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600276</ArticleId><ArticleId IdType="pmc">PMC1150991</ArticleId><ArticleId IdType="pubmed">15215895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama K., Fujiwara Y., Terada T., Shimizu K., Wada K., Kabuta T. Virtual screening identification of novel chemical inhibitors for aberrant interactions between pathogenic mutant SOD1 and tubulin. Neurochem. Int. 2019;126:19&#x2013;26. doi: 10.1016/j.neuint.2019.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.02.020</ArticleId><ArticleId IdType="pubmed">30831216</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E., Rajasekaran R. Rational design of linear tripeptides against the aggregation of human mutant SOD1 protein causing amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;405:116425. doi: 10.1016/j.jns.2019.116425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.116425</ArticleId><ArticleId IdType="pubmed">31422280</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E., Rajasekaran R. Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein. J. Comput. Aided Mol. Des. 2018;32:1347&#x2013;1361. doi: 10.1007/s10822-018-0175-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-018-0175-1</ArticleId><ArticleId IdType="pubmed">30368622</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E., Rajasekaran R. Computational investigation of curcumin, a natural polyphenol that inhibits the destabilization and the aggregation of human SOD1 mutant (Ala4Val) RSC Adv. 2016;6:102744&#x2013;102753. doi: 10.1039/C6RA21927F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6RA21927F</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E., Rajasekaran R. Comparative binding of kaempferol and kaempferide on inhibiting the aggregate formation of mutant (G85R) SOD1 protein in familial amyotrophic lateral sclerosis: A quantum chemical and molecular mechanics study. Biofactors. 2018;44:431&#x2013;442. doi: 10.1002/biof.1441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1441</ArticleId><ArticleId IdType="pubmed">30260512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.Y., Mei Z.Q., Wu J.W., Wang Z.X. Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states. J. Biol. Chem. 2008;283:26591&#x2013;26601. doi: 10.1074/jbc.M801703200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M801703200</ArticleId><ArticleId IdType="pmc">PMC3258911</ArticleId><ArticleId IdType="pubmed">18669639</ArticleId></ArticleIdList></Reference><Reference><Citation>Thalhamer T., McGrath M., Harnett M. MAPKs and their relevance to arthritis and inflammation. Rheumatology. 2008;47:409&#x2013;414. doi: 10.1093/rheumatology/kem297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem297</ArticleId><ArticleId IdType="pubmed">18187523</ArticleId></ArticleIdList></Reference><Reference><Citation>Chico L.K., Van Eldik L.J., Watterson D.M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 2009;8:892&#x2013;909. doi: 10.1038/nrd2999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2999</ArticleId><ArticleId IdType="pmc">PMC2825114</ArticleId><ArticleId IdType="pubmed">19876042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes V., Sharma D., Kalia K., Tiwari V. Neuroprotective effects of silibinin: An in silico and in vitro study. Int. J. Neurosci. 2018;128:935&#x2013;945. doi: 10.1080/00207454.2018.1443926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2018.1443926</ArticleId><ArticleId IdType="pubmed">29465317</ArticleId></ArticleIdList></Reference><Reference><Citation>Laev S.S., Salakhutdinov N.F., Lavrik O.I. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential. Bioorganic. Med. Chem. 2016;24:5017&#x2013;5027. doi: 10.1016/j.bmc.2016.09.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2016.09.045</ArticleId><ArticleId IdType="pubmed">27687971</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado I.G., Redondo M., Bello M.L., Perez C., Liachko N.F., Kraemer B.C., Miguel L., Lecourtois M., Gil C., Martinez A., et al. Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. J. Med. Chem. 2014;57:2755&#x2013;2772. doi: 10.1021/jm500065f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm500065f</ArticleId><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissaro M., Moro S. Rethinking to riluzole mechanism of action: The molecular link among protein kinase CK1&#x3b4; activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural. Regen. Res. 2019;14:2083&#x2013;2085. doi: 10.4103/1673-5374.262578.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.262578</ArticleId><ArticleId IdType="pmc">PMC6788255</ArticleId><ArticleId IdType="pubmed">31397342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozza G., Gianoncelli A., Montopoli M., Caparrotta L., Venerando A., Meggio F., Pinna L.A., Zagotto G., Moro S. Identification of novel protein kinase CK1 delta (CK1&#x3b4;) inhibitors through structure-based virtual screening. Bioorganic. Med. Chem. Lett. 2008;18:5672&#x2013;5675. doi: 10.1016/j.bmcl.2008.08.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.08.072</ArticleId><ArticleId IdType="pubmed">18799313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozza G., Pinna L.A., Moro S. Kinase CK2 inhibition: An update. Curr. Med. Chem. 2013;20:671&#x2013;693. doi: 10.2174/092986713804999312.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986713804999312</ArticleId><ArticleId IdType="pubmed">23210774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney J.A., Buchner D.A., De Haan G., Adamska M., Levin S.I., Furay A.R., Albin R.L., Jones J.M., Montal M., Stevens M.J. Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Nav1. 6) Hum. Mol. Genet. 2002;11:2765&#x2013;2775. doi: 10.1093/hmg/11.22.2765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.22.2765</ArticleId><ArticleId IdType="pubmed">12374766</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell J.H., Schaller K.L., Lasher R.S., Peles E., Levinson S.R. Sodium channel Nav1. 6 is localized at nodes of Ranvier, dendrites, and synapses. Proc. Natl. Acad. Sci. USA. 2000;97:5616&#x2013;5620. doi: 10.1073/pnas.090034797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.090034797</ArticleId><ArticleId IdType="pmc">PMC25877</ArticleId><ArticleId IdType="pubmed">10779552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunasekaran R., Narayani R.S., Vijayalakshmi K., Alladi P.A., Shobha K., Nalini A., Sathyaprabha T., Raju T. Exposure to cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients alters Nav1. 6 and Kv1. 6 channel expression in rat spinal motor neurons. Brain Res. 2009;1255:170&#x2013;179. doi: 10.1016/j.brainres.2008.11.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.11.099</ArticleId><ArticleId IdType="pubmed">19109933</ArticleId></ArticleIdList></Reference><Reference><Citation>Saba L., Viscomi M.T., Martini A., Caioli S., Mercuri N.B., Guatteo E., Zona C. Modified age-dependent expression of NaV1. 6 in an ALS model correlates with motor cortex excitability alterations. Neurobiol. Dis. 2019;130:104532. doi: 10.1016/j.nbd.2019.104532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104532</ArticleId><ArticleId IdType="pubmed">31302244</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki S., Yamamoto T., Quinn K., Spigelman I., Pantazis A., Olcese R., Wiedau-Pazos M., Chandler S.H., Venugopal S. Circuit-Specific Early Impairment of Proprioceptive Sensory Neurons in the SOD1G93A Mouse Model for ALS. J. Neurosci. 2019;39:8798&#x2013;8815. doi: 10.1523/JNEUROSCI.1214-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1214-19.2019</ArticleId><ArticleId IdType="pmc">PMC6820216</ArticleId><ArticleId IdType="pubmed">31530644</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant P., Song J.Y., Swedo S.E. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2010;20:309&#x2013;315. doi: 10.1089/cap.2010.0009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cap.2010.0009</ArticleId><ArticleId IdType="pmc">PMC2958461</ArticleId><ArticleId IdType="pubmed">20807069</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai I., Toichi K., Tokuda E., Mukaiyama A., Akiyama S., Furukawa Y. Screening of drugs inhibiting in vitro oligomerization of Cu/Zn-superoxide dismutase with a mutation causing amyotrophic lateral sclerosis. Front. Mol. Biosci. 2016;3:40. doi: 10.3389/fmolb.2016.00040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2016.00040</ArticleId><ArticleId IdType="pmc">PMC4977284</ArticleId><ArticleId IdType="pubmed">27556028</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J.B., Gusella J.F. Huntingtons disease. N. Engl. J. Med. 1986;315:1267&#x2013;1276. doi: 10.1212/WNL.0000000000008054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008054</ArticleId><ArticleId IdType="pubmed">2877396</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M.J., Tabrizi S.J. Huntington&#x2019;s disease. BMJ. 2010;340:c3109. doi: 10.1136/bmj.c3109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c3109</ArticleId><ArticleId IdType="pubmed">20591965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wexler N.S., Collett L., Wexler A.R., Rawlins M.D., Tabrizi S.J., Douglas I., Smeeth L., Evans S.J. Incidence of adult Huntington&#x2019;s disease in the UK: A UK-based primary care study and a systematic review. BMJ Open. 2016;6:e009070. doi: 10.1136/bmjopen-2015-009070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-009070</ArticleId><ArticleId IdType="pmc">PMC4769413</ArticleId><ArticleId IdType="pubmed">26908513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavanaugh M.S., Cho C., Maeda H., Swope C. &#x201c;I am no longer alone&#x201d;: Evaluation of the first North American camp for youth living in families with Huntington&#x2019;s disease. Child. Youth Serv. Rev. 2017;79:325&#x2013;332. doi: 10.1016/j.childyouth.2017.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.childyouth.2017.06.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala K.M. Role of the SLP in management of Huntington&#x2019;s disease: A literature review.  [(accessed on 14 April 2021)];2017  doi: 10.15781/T2V698V0T. Available online:  https://repositories.lib.utexas.edu/handle/2152/62346.</Citation><ArticleIdList><ArticleId IdType="doi">10.15781/T2V698V0T</ArticleId></ArticleIdList></Reference><Reference><Citation>Travessa A.M., Rodrigues F.B., Mestre T.A., Ferreira J.J. Fifteen years of clinical trials in Huntington&#x2019;s disease: A very low clinical drug development success rate. J. Huntingt. Dis. 2017;6:157&#x2013;163. doi: 10.3233/JHD-170245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-170245</ArticleId><ArticleId IdType="pubmed">28671135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi S. Targeting Huntingtin Expression in Patients with Huntington&#x2019;s Disease. N. Engl. J. Med. 2019;380:2307&#x2013;2316. doi: 10.1056/NEJMoa1900907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1900907</ArticleId><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Iftikhar H., Batool S., Deep A., Narasimhan B., Sharma P.C., Malhotra M. In silico analysis of the inhibitory activities of GABA derivatives on 4-aminobutyrate transaminase. Arab. J. Chem. 2017;10:S1267&#x2013;S1275. doi: 10.1016/j.arabjc.2013.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arabjc.2013.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonstra E., de Kleijn R., Colzato L.S., Alkemade A., Forstmann B.U., Nieuwenhuis S. Neurotransmitters as food supplements: The effects of GABA on brain and behavior. Front. Psychol. 2015;6:1520. doi: 10.3389/fpsyg.2015.01520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2015.01520</ArticleId><ArticleId IdType="pmc">PMC4594160</ArticleId><ArticleId IdType="pubmed">26500584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar S., Kasthuri G., Prabhu S., Manogar P., Parameswari N. Screening and identification of novel inhibitors against human 4-aminobutyrate-aminotransferase: A computational approach. Egypt J. Basic Appl. Sci. 2018;5:210&#x2013;219. doi: 10.1016/j.ejbas.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejbas.2018.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider G. Virtual screening: An endless staircase? Nat. Rev. Drug Discov. 2010;9:273&#x2013;276. doi: 10.1038/nrd3139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3139</ArticleId><ArticleId IdType="pubmed">20357802</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Arthurs S., Colson A.B., Freer S.T., Larson V., Luty B.A., Marrone T. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comput. Aided Mol. Des. 2000;14:731&#x2013;751. doi: 10.1023/A:1008158231558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1008158231558</ArticleId><ArticleId IdType="pubmed">11131967</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs D., Spicer J., O&#x2019;Doherty M. Molecular imaging in clinical trials. Target. Oncol. 2009;4:151&#x2013;168. doi: 10.1007/s11523-009-0117-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11523-009-0117-x</ArticleId><ArticleId IdType="pubmed">19768637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham T.E., III, Young M.A. Molecular dynamics simulation of nucleic acids: Successes, limitations, and promise. Biopolym. Orig. Res. Biomol. 2000;56:232&#x2013;256. doi: 10.1002/1097-0282(2000)56:4&lt;232::AID-BIP10037&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0282(2000)56:4&lt;232::AID-BIP10037&gt;3.0.CO;2-H</ArticleId><ArticleId IdType="pubmed">11754338</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebe G. Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov. Today. 2006;11:580&#x2013;594. doi: 10.1016/j.drudis.2006.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.05.012</ArticleId><ArticleId IdType="pmc">PMC7108249</ArticleId><ArticleId IdType="pubmed">16793526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira L.G., Dos Santos R.N., Oliva G., Andricopulo A.D. Molecular docking and structure-based drug design strategies. Molecules. 2015;20:13384&#x2013;13421. doi: 10.3390/molecules200713384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules200713384</ArticleId><ArticleId IdType="pmc">PMC6332083</ArticleId><ArticleId IdType="pubmed">26205061</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O., Olsson T.S., Bowden S.J., Hall R.J., Verdonk M.L., Liebeschuetz J.W., Cole J.C. Potential and limitations of ensemble docking. J. Chem. Inf. Modeling. 2012;52:1262&#x2013;1274. doi: 10.1021/ci2005934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci2005934</ArticleId><ArticleId IdType="pubmed">22482774</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald D., Breton R., Sutcliffe R., Walker J. Uses and limitations of quantitative structure-activity relationships (QSARs) to categorize substances on the Canadian Domestic Substance List as persistent and/or bioaccumulative, and inherently toxic to non-human organisms. Sar Qsar Environ. Res. 2002;13:43&#x2013;55. doi: 10.1080/10629360290002082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10629360290002082</ArticleId><ArticleId IdType="pubmed">12074391</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakonstantinou E., Megalooikonomou V., Vlachakis D. Dark Suite: A comprehensive toolbox for computer-aided drug design. Embnet. J. 2020;25:e928. doi: 10.14806/ej.25.0.928.</Citation><ArticleIdList><ArticleId IdType="doi">10.14806/ej.25.0.928</ArticleId><ArticleId IdType="pmc">PMC7164806</ArticleId><ArticleId IdType="pubmed">32309170</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdigaliyev N., Aljofan M. An overview of drug discovery and development. Future Med. Chem. 2020;12:939&#x2013;947. doi: 10.4155/fmc-2019-0307.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2019-0307</ArticleId><ArticleId IdType="pubmed">32270704</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Zha W. Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery. Eur. J. Drug Metab. Pharmacokinet. 2019;44:135&#x2013;137. doi: 10.1007/s13318-018-0503-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13318-018-0503-9</ArticleId><ArticleId IdType="pubmed">30136219</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Waterbeemd H., Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov. 2003;2:192&#x2013;204. doi: 10.1038/nrd1032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1032</ArticleId><ArticleId IdType="pubmed">12612645</ArticleId></ArticleIdList></Reference><Reference><Citation>Faller B., Winiwarter S., Chang G., Desai P., Menzel C., Rieko A., Keefer C., Broccatelli F. Prediction of fraction unbound in microsomal and hepatocyte incubations&#x2013;a comparison of methods across industry data sets (by the IQ in silico ADME working group) Mol. Pharm. 2019;16:4077&#x2013;4085.</Citation><ArticleIdList><ArticleId IdType="pubmed">31348668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomme E.A., Will Y. Toxicology strategies for drug discovery: Present and future. Chem. Res. Toxicol. 2016;29:473&#x2013;504. doi: 10.1021/acs.chemrestox.5b00407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.5b00407</ArticleId><ArticleId IdType="pubmed">26588328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruss R.M. Phenotypic screening strategies for neurodegenerative diseases: A pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol. Disord. Drug Targets Former. Curr. Drug Targets CNS Neurol. Disord. 2010;9:693&#x2013;700. doi: 10.2174/187152710793237377.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710793237377</ArticleId><ArticleId IdType="pubmed">20942792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., Wen L., Gao X., Jin C., Xue Y., Yao X. CSS-Palm 2.0: An updated software for palmitoylation sites prediction. Protein Eng. Des. Sel. 2008;21:639&#x2013;644. doi: 10.1093/protein/gzn039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzn039</ArticleId><ArticleId IdType="pmc">PMC2569006</ArticleId><ArticleId IdType="pubmed">18753194</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikzad H., Karimian M., Sareban K., Khoshsokhan M., Colagar A.H. MTHFR-Ala222Val and male infertility: A study in Iranian men, an updated meta-analysis and an in silico-analysis. Reprod. Biomed. Online. 2015;31:668&#x2013;680. doi: 10.1016/j.rbmo.2015.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rbmo.2015.07.015</ArticleId><ArticleId IdType="pubmed">26380869</ArticleId></ArticleIdList></Reference><Reference><Citation>Glykos N.M. Software news and updates carma: A molecular dynamics analysis program. J. Comput. Chem. 2006;27:1765&#x2013;1768. doi: 10.1002/jcc.20482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20482</ArticleId><ArticleId IdType="pubmed">16917862</ArticleId></ArticleIdList></Reference><Reference><Citation>CCDC  What&#x2019;s New.  [(accessed on 14 April 2021)]; Available online:  https://www.ccdc.cam.ac.uk/solutions/whats-new/</Citation></Reference><Reference><Citation>Zuo Z., MacMillan D.W. Decarboxylative arylation of &#x3b1;-amino acids via photoredox catalysis: A one-step conversion of biomass to drug pharmacophore. J. Am. Chem. Soc. 2014;136:5257&#x2013;5260. doi: 10.1021/ja501621q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja501621q</ArticleId><ArticleId IdType="pmc">PMC4004246</ArticleId><ArticleId IdType="pubmed">24712922</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez K., Espinosa-Bustos C., Soto-Delgado J., Tapia R.A., Varela J., Birriel E., Segura R., Pizarro J., Cerecetto H., Gonz&#xe1;lez M. New aryloxy-quinone derivatives as potential anti-Chagasic agents: Synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis. RSC Adv. 2015;5:65153&#x2013;65166. doi: 10.1039/C5RA10122K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5RA10122K</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett B.C., Wan Q., Ahmad M.F., Langan P., Dealwis C.G. X-ray structure of the ternary MTX NADPH complex of the anthrax dihydrofolate reductase: A pharmacophore for dual-site inhibitor design. J. Struct. Biol. 2009;166:162&#x2013;171. doi: 10.1016/j.jsb.2009.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2009.01.001</ArticleId><ArticleId IdType="pmc">PMC2738603</ArticleId><ArticleId IdType="pubmed">19374017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois P., Hakim V. Design of genetic networks with specified functions by evolution in silico. Proc. Natl. Acad. Sci. USA. 2004;101:580&#x2013;585. doi: 10.1073/pnas.0304532101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0304532101</ArticleId><ArticleId IdType="pmc">PMC327190</ArticleId><ArticleId IdType="pubmed">14704282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer B., Fukuzawa K., Wenzel W. Receptor-specific scoring functions derived from quantum chemical models improve affinity estimates for in-silico drug discovery. Proteins Struct. Funct. Bioinform. 2008;70:1264&#x2013;1273. doi: 10.1002/prot.21607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.21607</ArticleId><ArticleId IdType="pubmed">17876816</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatami S.G., Mubeen S., Hofmann-Apitius M. Data science in neurodegenerative disease: Its capabilities, limitations, and perspectives. Curr. Opin. Neurol. 2020;33:249. doi: 10.1097/WCO.0000000000000795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000795</ArticleId><ArticleId IdType="pmc">PMC7077964</ArticleId><ArticleId IdType="pubmed">32073441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro M.P., Heilshorn S.C., Owens R.M. Materials for blood brain barrier modeling in vitro. Mater. Sci. Eng. R Rep. 2020;140:100522. doi: 10.1016/j.mser.2019.100522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mser.2019.100522</ArticleId><ArticleId IdType="pmc">PMC7864217</ArticleId><ArticleId IdType="pubmed">33551572</ArticleId></ArticleIdList></Reference><Reference><Citation>May J.-N., Golombek S.K., Baues M., Dasgupta A., Drude N., Rix A., Rommel D., von Stillfried S., Appold L., Pola R. Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation. Theranostics. 2020;10:1948. doi: 10.7150/thno.41161.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.41161</ArticleId><ArticleId IdType="pmc">PMC6993230</ArticleId><ArticleId IdType="pubmed">32042346</ArticleId></ArticleIdList></Reference><Reference><Citation>Juthani R., Madajewski B., Yoo B., Zhang L., Chen P.-M., Chen F., Turker M.Z., Ma K., Overholtzer M., Longo V.A. Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clin. Cancer Res. 2020;26:147&#x2013;158. doi: 10.1158/1078-0432.CCR-19-1834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1834</ArticleId><ArticleId IdType="pmc">PMC6942644</ArticleId><ArticleId IdType="pubmed">31515460</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C., Heilbron K., Vallerga C.L., Bandres-Ciga S., von Coelln R., Pihlstr&#xf8;m L., Sim&#xf3;n-S&#xe1;nchez J., Schulte C., Sharma M., Krohn L. Parkinson&#x2019;s disease age at onset genome-wide association study: Defining heritability, genetic loci, and &#x3b1;-synuclein mechanisms. Mov. Disord. 2019;34:866&#x2013;875. doi: 10.1002/mds.27659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27659</ArticleId><ArticleId IdType="pmc">PMC6579628</ArticleId><ArticleId IdType="pubmed">30957308</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls M.A., Blauwendraat C., Vallerga C.L., Heilbron K., Bandres-Ciga S., Chang D., Tan M., Kia D.A., Noyce A.J., Xue A. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: A meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091&#x2013;1102. doi: 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciani M., Benussi L., Bonvicini C., Ghidoni R. Genome Wide Association Study and Next Generation Sequencing: A glimmer of light towards new possible horizons in Frontotemporal Dementia research. Front. Neurosci. 2019;13:506. doi: 10.3389/fnins.2019.00506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00506</ArticleId><ArticleId IdType="pmc">PMC6532367</ArticleId><ArticleId IdType="pubmed">31156380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez L., Farias F.H., Dube U., Mihindukulasuriya K.A., Harari O. Polygenic risk scores in neurodegenerative diseases: A review. Curr. Genet. Med. Rep. 2019;7:22&#x2013;29. doi: 10.1007/s40142-019-0158-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-019-0158-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams H.H., Evans T.E., Terzikhan N. The Uncovering Neurodegenerative Insights Through Ethnic Diversity consortium. Lancet Neurol. 2019;18:915. doi: 10.1016/S1474-4422(19)30324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30324-2</ArticleId><ArticleId IdType="pubmed">31526750</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Fryatt G., Cleal M.E., Obst J., Pipi E., Monzon-Sandoval J., Winchester L., Ribe E., Webber C., Nevado A. CSF1R inhibition by JNJ-40346527 alters microglial proliferation and phenotype and results in attenuation of neurodegeneration in P301S mice. Brain. 2019;142:3243&#x2013;3264. doi: 10.1093/brain/awz241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz241</ArticleId><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S., Datta M., Kim J., Jan A.T. CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases. Semin. Cell Dev. Biol. 2019;96:22&#x2013;31. doi: 10.1016/j.semcdb.2019.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.05.014</ArticleId><ArticleId IdType="pubmed">31102655</ArticleId></ArticleIdList></Reference><Reference><Citation>Offen D., Perets N., Betzer O., Popovtzer R., Shapira R., Ashery U. Targeting damages in the brain: Exosomes derived from MSC present migration and homing abilities to different neurodegenerative and neuropsychiatric locations. Cytotherapy. 2019;21:e6. doi: 10.1016/j.jcyt.2019.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2019.04.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Raikwar S.P., Kikkeri N.S., Sakuru R., Saeed D., Zahoor H., Premkumar K., Mentor S., Thangavel R., Dubova I., Ahmed M.E. Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders. J. Neuroimmune Pharmacol. 2019;14:608&#x2013;641. doi: 10.1007/s11481-019-09849-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-019-09849-y</ArticleId><ArticleId IdType="pubmed">31011884</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldewachi H., Al-Zidan R.N., Conner M.T., Salman M.M. High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. Bioengineering. 2021;8:30. doi: 10.3390/bioengineering8020030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering8020030</ArticleId><ArticleId IdType="pmc">PMC7926814</ArticleId><ArticleId IdType="pubmed">33672148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal R., Woo F.W., Castro C.S., Cohen M.A., Karanxha J., Mittal J., Chhibber T., Jhaveri V.M. Organ-on-chip models: Implications in drug discovery and clinical applications. J. Cell. Physiol. 2019;234:8352&#x2013;8380. doi: 10.1002/jcp.27729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27729</ArticleId><ArticleId IdType="pubmed">30443904</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman M.M., Marsh G., Kusters I., Delinc&#xe9; M., Di Caprio G., Upadhyayula S., de Nola G., Hunt R., Ohashi K.G., Gray T., et al. Design and Validation of a Human Brain Endothelial Microvessel-on-a-Chip Open Microfluidic Model Enabling Advanced Optical Imaging. Front. Bioeng. Biotechnol. 2020;8 doi: 10.3389/fbioe.2020.573775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.573775</ArticleId><ArticleId IdType="pmc">PMC7576009</ArticleId><ArticleId IdType="pubmed">33117784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.J. Functional MRI of brain physiology in aging and neurodegenerative diseases. Neuroimage. 2019;187:209&#x2013;225. doi: 10.1016/j.neuroimage.2018.05.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.05.050</ArticleId><ArticleId IdType="pubmed">29793062</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir E.R., Biju K., Cong L., Rogers W.E., Hernandez E.T., Duong T.Q., Clark R.A. Functional MRI of the mouse olfactory system. Neurosci. Lett. 2019;704:57&#x2013;61. doi: 10.1016/j.neulet.2019.03.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.03.055</ArticleId><ArticleId IdType="pubmed">30951799</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S., Zheng C., Cui B., Qi Z., Zhao Z., An Y., Qiao L., Han Y., Zhou Y., Lu J. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer&#x2019;s disease. Eur. J. Nucl. Med. Mol. Imaging. 2020;47:2440&#x2013;2452. doi: 10.1007/s00259-020-04752-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04752-8</ArticleId><ArticleId IdType="pmc">PMC7396401</ArticleId><ArticleId IdType="pubmed">32157432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>